Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
CH

NASDAQ · CHRS

Coherus Oncology, Inc.

Healthcare · Biotechnology

$1.03

Down-$0.09 (-8.04%)

Updated Oct 7, 2026, 3:56 AM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
165.18M
P/E ratio
1.07
Dividend yield
0.00%
52-week range
$1.08 – $2.11
Volume
2.97M
Avg. volume
1.23M

Price performance · CHRS

CHRS price history

1M range · 0 trading sessions · Daily adjusted prices

CHRS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CHRS news

The latest Smart Investors Daily articles mentioning CHRS.

Stock researchCompany · Overview

CHRS research

Overview

Company profile and research snapshot.

Company profile

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.02
Implied upside
—
Analysts
—
CHRS recent ratings
DateFirmRatingTarget
Aug 7, 2026GuggenheimBuy—
May 11, 2026GuggenheimBuy—
Jan 22, 2026OppenheimerOutperform—
Sep 4, 2025Maxim GroupBuy—
Apr 29, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 23, 2026

Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets

- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -REDWOOD CITY, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that it has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business (the “Legacy BioSim Assets”). The Company has retained Oppenheimer & Co. Inc. (“Oppenheimer”) to serve as its financial advisor in connection with the sale. Parties

Yahoo · Aug 31, 2026

Coherus to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences: Baird 2026 Global Healthcare Conference in New York, NY on Tuesday, September 15, 2026, at 7:55 a.m. Eastern Daylight Time.H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on Tuesday, September 15, 2026, at 11:30 a.m. Eastern Daylight Time.Morgan Stanley 24th Annual Global Healthcare Confere

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By